KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Change in Receivables (2016 - 2025)

Jazz Pharmaceuticals (JAZZ) has 16 years of Change in Receivables data on record, last reported at $65.8 million in Q4 2025.

  • For Q4 2025, Change in Receivables rose 7717.25% year-over-year to $65.8 million; the TTM value through Dec 2025 reached $106.3 million, up 403.33%, while the annual FY2025 figure was $106.3 million, 403.33% up from the prior year.
  • Change in Receivables reached $65.8 million in Q4 2025 per JAZZ's latest filing, up from $51.0 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $75.5 million in Q4 2023 and bottomed at -$66.0 million in Q1 2025.
  • Average Change in Receivables over 5 years is $18.1 million, with a median of $17.4 million recorded in 2021.
  • The widest YoY moves for Change in Receivables: up 7717.25% in 2025, down 882.29% in 2025.
  • A 5-year view of Change in Receivables shows it stood at $64.8 million in 2021, then fell by 28.58% to $46.3 million in 2022, then soared by 63.11% to $75.5 million in 2023, then plummeted by 101.14% to -$864000.0 in 2024, then surged by 7717.25% to $65.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Receivables were $65.8 million in Q4 2025, $51.0 million in Q3 2025, and $55.5 million in Q2 2025.